

1 **Brief Communication**

2

3 **Antigen Specific T Cells in People with Obesity at Five Months Following**
4 **ChAdOx1 COVID-19 Vaccination**

5

6 Neil E. Wrigley Kelly¹, Conor De Barra², Ferrah Shaamile³, Aisling Holland³, Liam Shaw¹, Patrick
7 W.G. Mallon⁴, Jean O’Connell³, Andrew E. Hogan^{2,5*} and Donal O’Shea^{1,3*}

8

9 **Affiliation:** ¹ St Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland.

10 ² Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth,

11 Co Kildare, Ireland. ³ St Columcille’s Hospital, Loughlinstown, Co. Dublin, Ireland. ⁴ Centre for

12 Experimental Pathogen Host Research, School of Medicine, University College Dublin, Ireland.

13 ⁵ National Children’s Research Centre, Dublin 12, Ireland. *Joint Senior Authors.

14

15 **Contact Information:**

16 Dr Andrew Hogan

17 Email: Andrew.E.Hogan@mu.ie

18 Address:

19 Biosciences Building,

20 Maynooth University, Maynooth,

21 Co. Kildare, Ireland.

22 Phone: +35317086118

23

24 **Word Count:** 1496

25

26 **Funding:** This work is supported by the National Children’s Research Centre, a philanthropic
27 donation from the St Vincent’s Foundation. Financial support for the Attune Nxt was provided
28 to Maynooth University Department of biology by Science Foundation Ireland (16/RI/3399).

29

30 **Competing interests:** The authors declare no competing interests.

31

32 **Abstract**

33 **Background/Objectives:** People with obesity (PWO) face an increased risk of severe
34 outcomes from COVID-19, including hospitalisation, ICU admission and death. Obesity has
35 been seen to impair immune memory following vaccination against influenza, hepatitis B,
36 tetanus, and rabies. Little is known regarding immune memory in PWO following COVID-19
37 adenovirus vector vaccination.

38 **Subjects/Methods:** We investigated SARS-CoV-2 specific T cell responses in 50 subjects, five
39 months following a two-dose primary course of ChAdOx1 nCoV-19 (AZD1222) vaccination.
40 We further divided our cohort into PWO (n=30) and matched controls (n=20). T cell (CD4⁺,
41 CD8⁺) cytokine responses (IFN γ , TNF α) to SARS-CoV-2 spike peptide pools were determined
42 using multicolour flow cytometry.

43 **Results:** Circulating T cells specific for SARS-CoV-2 were readily detected across our cohort,
44 with robust responses to spike peptide stimulation across both T cell lines. PWO and controls
45 had comparable levels of both CD4⁺ and CD8⁺ SARS-CoV-2 spike specific T cells. Polyfunctional
46 T cells – associated with enhanced protection against viral infection – were detected at similar
47 frequencies in both PWO and controls.

48 **Conclusions:** These data indicate that PWO who have completed a primary course of ChAdOx1
49 COVID-19 vaccination have robust, durable, and functional antigen specific T cell immunity
50 that is comparable to that seen in people without obesity.

51

52 **Introduction**

53 People with obesity (PWO) have a substantially increased risk of developing severe
54 coronavirus disease 2019 (COVID-19). Many studies have summarised this relationship (1, 2).
55 One meta-analysis for example outlined PWO to have a 113% increased risk of hospitalisation,
56 74% increased ICU admission and 48% higher mortality (1). The introduction of multiple highly
57 efficacious COVID-19 vaccines mitigates the impact of the pandemic for many. This is of
58 particular importance to those with obesity. However, little is known regarding immune
59 memory following COVID-19 vaccination in this population.

60

61 PWO have impaired responses to vaccination in multiple settings. Impaired humoral
62 responses have been observed following rabies (3), tetanus (4) and hepatitis B (5)
63 immunisation. Furthermore, a study published in 2012 looked at PWO and controls without
64 obesity following influenza vaccination, showing PWO to have both greater declines in
65 antibody titres and lower frequencies of antigen specific CD8⁺ T cells at 12 months follow-up
66 (6).

67

68 Antigen specific T cells have a crucial role in the adaptive response to SARS-CoV-2 infection
69 and are protective against severe disease (7). They are durable, with longitudinal cohorts
70 demonstrating their presence for at least 8 months post-vaccination (8). They are also more
71 resilient to antigenic variation than antibody/B cell responses, as observed in the case of the
72 omicron variant of concern (9).

73

74 The aim of this study was to evaluate if adults (18 years and older) with obesity (body mass
75 index, BMI ≥ 30.0 kg/m²) who have a history of COVID-19 adenovirus vector vaccination
76 demonstrate poorer antigen specific T cell immunity compared to controls.

77

78 **Materials/Subjects and Methods**

79 We performed a cross-sectional cohort study looking at SARS-CoV-2 specific CD4⁺ and CD8⁺
80 cell responses at 5 months following completion of a two-dose course of ChAdOx1 nCoV-19
81 (AZD1222) vaccine, with a dosing interval of 12 weeks. Subjects were recruited from staff
82 and outpatients attending the St. Columcille's Hospital, Loughlinstown COVID-19 vaccination
83 centre. 50 volunteers (30 PWO [BMI ≥ 30 kg/m²] and 20 controls [BMI < 30 kg/m²]) were
84 included (see Table 1). Samples were collected over November and December 2021.

85 Inclusion criteria were: ability to give informed consent, age ≥ 18 years, 4 to 6 months since
86 second dose of ChAdOx1 nCoV-19 (AZD1222) vaccine. Exclusion criteria included: known
87 previous SARS-CoV-2 infection (confirmed by PCR or antigen test), treatment with certain
88 classes of immunosuppressants (anti-TNF agents, IL-1, IL-2, IL-6, IL-17 inhibitors) within the
89 preceding 8 months, obesity induced by other endocrine disorders, active
90 lymphoproliferative disorder and any active illness or medication which in the opinion of the
91 investigator precluded participation in the study.

92

93 Subjects were recruited as part of the Obesity Immunology Group cohort study. All subjects
94 provided written, informed consent. The study was conducted in accordance with the
95 Declaration of Helsinki and ethical approval was granted by the St. Vincent's Hospital Group
96 Research Ethics Committee.

97

98 **Preparation of peripheral blood mononuclear cells (PBMC) and flow cytometric analysis**

99 PBMCs were isolated from whole blood samples by centrifugation through density gradient
100 media (Lymphoprep™, Nycomed Pharma, Oslo, Norway), before suspension in cell
101 cryopreservation media and storage in a -70 °C freezer.

102

103 Thawed PBMCs were stimulated with SARS-CoV-2 spike peptide pools (Miltenyi
104 PepTivator®SARS-CoV-2 research grade). After 4 hours protein transport inhibitor (Thermo
105 Fisher Scientific, Waltham, Massachusetts, USA) was added to each well, samples were
106 incubated at 37 °C for a further 12 hours. Having completed incubation, cells were
107 centrifuged, re-suspended in flow cytometry staining buffer, then stained for cell surface
108 markers (CD3, CD4, CD8). Following staining, live cells were fixed, permeabilised and
109 intracellular cytokine staining was performed. Multicolour flow cytometry was performed
110 using Attune™ NxT Flow Cytometer.

111

112 **Quantification and statistical analysis**

113 Data and statistical analyses were performed using FlowJo v10.8.1 and GraphPad Prism 9
114 software. Statistical comparisons were performed using the Wilcoxon and Mann-Whitney U test,
115 where appropriate. Statistical significance for p values was <0.05. Background subtraction
116 was used when calculating antigen specific T cell frequencies.

117

118 **Results**

119 The clinical characteristics of the cohorts are presented in table 1.

120

121 **Robust SARS-CoV-2 specific T cell responses in people with obesity**

122 Adenovirus vector vaccines have been shown to elicit robust, durable SARS-CoV-2 specific T
123 cell responses following completion of vaccine course (8). We confirmed this to be the case
124 in our cohort, where both CD4⁺ and CD8⁺ cells were seen to express interferon gamma
125 (IFN γ) following stimulation with spike peptide pools (Figure 1A-C) (median CD8⁺ IFN γ ⁺
126 frequency following spike stimulation: 0.780%, IQR 0.451-1.235%; median CD4⁺: 0.028%,
127 IQR 0.013-0.051%).

128

129 T cells that produce multiple cytokines are known as polyfunctional T cells. Their presence
130 among the antigen specific T cell populations elicited by vaccination is highly desirable, as
131 they are associated with enhanced protection against viral infections (10). Among our
132 cohort polyfunctional T cells (IFN γ ⁺TNF α ⁺) were readily detectable across both conventional
133 (CD4⁺ and CD8⁺) T cell lines following spike stimulation (Figure 1D-E) (median CD8⁺
134 IFN γ ⁺TNF α ⁺ frequency against spike: 0.463%, IQR 0.203-0.783%; median CD4⁺: 0.014%, IQR
135 0.008-0.031%).

136

137 Obesity has been associated with substantial innate and adaptive immune dysregulation,
138 including impaired anti-viral immunity following infection or vaccination (6, 11). To
139 investigate this, we separated our cohort into PWO and controls (median BMI 39.1 kg/m² [IQR
140 32.6-47.0] and 26 kg/m² [IQR 22.8-27.8]). PWO were seen to have robust SARS-CoV-2 specific
141 T cell responses, with no differences in the frequencies of CD4⁺ and CD8⁺ T cells producing
142 IFN γ in response to spike stimulation (Figure 1F-G). Furthermore, similar frequencies of
143 polyfunctional T cells were observed in those with and without obesity (Figure 1H-I).

144

145 **Discussion**

146 Given the greatly increased risk of severe COVID-19 in people with obesity it is important to
147 properly characterise vaccine induced immunity in this vulnerable population. Here we
148 studied antigen specific T cell responses in PWO and controls persisting to 5 months following
149 a complete primary course of ChAdOx1 nCoV-19 (AZD1222) vaccine. Robust frequencies of
150 antigen specific CD4⁺ and CD8⁺ T cells were identified across our cohort (n=50). Between
151 group analysis provides evidence that SARS-CoV-2 specific T cell frequencies are preserved in
152 PWO.

153

154 Specific forms of immunosuppression have been associated with impaired responses to
155 COVID-19 vaccines. These include people with haematological malignancies (12), solid organ
156 transplant recipients (13) and people with advanced HIV infection (14). Obesity has been
157 associated with extensive immune dysregulation, with chronic systemic inflammation and
158 loss of host protection (15). PWO have been seen to have impaired immune memory in
159 multiple settings. Weakened antibody responses have been seen following rabies (3), tetanus
160 (4) and hepatitis B vaccination (5). While impairment of both humoral and CD8⁺ T cell
161 responses has been seen following influenza vaccination (6).

162

163 Many questions remain regarding immune memory in PWO following COVID-19 vaccination.
164 Most of the available evidence relates to the mRNA vaccines. The BNT162b2 vaccine has been
165 associated with impairment of antibody responses in abdominal obesity (16). While follow-
166 up of the phase III mRNA-1273 and BNT162b2 studies - at 5 and 6 months respectively -
167 showed very similar vaccine efficacy against symptomatic infection between people with and
168 without obesity (17, 18). Regarding COVID-19 adenovirus vector vaccines, a study by Lee et
169 al. showed antibody (IgG against receptor binding domain) responses to the ChAdOx1 nCoV-

170 19 vaccine to be unimpacted by elevated BMI (19). However, there are no published papers
171 describing antigen specific T cell responses in PWO following COVID-19 adenovirus vector
172 vaccination.

173

174 Our data demonstrate that PWO who have completed a two-dose course of ChAdOx1 nCoV-
175 19 vaccine have robust antigen specific T cell responses along both CD8⁺ and CD4⁺ lines.
176 Responses that are comparable in frequency to controls, as well as being comparable to the
177 COVID-19 vaccine literature in general (8). The abundant presence of IFN γ expressing cells
178 implies not just antigen recognition but functional capacity to inhibit viral replication and
179 mobilise the immune response to infection. Polyfunctional T cells – readily detectable in PWO
180 - have been seen to correlate with favourable disease evolution and protection (10).

181

182 As SARS-CoV-2 reaches a point of endemicity with primary vaccine courses, boosters,
183 infections, and not infrequent reinfections, it is important for us to understand the
184 implications of each antigenic exposure for vulnerable hosts. Physiological contraction of
185 peripheral antibody titres following infection (20) and vaccination (8), as well as viral antigenic
186 variation leading to immune escape diminish the protection conferred by humoral immunity.
187 This reinforces the importance of cellular (antigen specific T cell, memory B cell) immunity,
188 particularly in view of the evidence for conservation of T responses to the antigenic variation
189 thus far observed in variants of concern (9).

190

191 Our study has limitations. While the groups in this study were well matched for age and
192 mean days from second vaccine dose, they were less well matched for sex. Future research
193 regarding immune memory in PWO in COVID-19 is critical. As the pandemic progresses,

194 longitudinal studies are required in order to continue to characterise the longevity of
195 cellular and humoral responses in this population, as well as to define precise correlates of
196 protection.

197

198 In summary, we measured SARS-CoV-2 specific CD4⁺ and CD8⁺ cell responses in people with
199 obesity following ChAdOx1 COVID-19 vaccination, showing features associated with
200 protective immunity and providing evidence that antigen specific T cell frequencies are not
201 impacted by obesity.

202

203 **Acknowledgements:** The authors wish to thank all study participants and their families. We
204 would like to thank Prof. Alan Landay and Prof. Michael Turner, for their expert input and
205 support. We wish to acknowledge the Irish Coalition for People Living with Obesity (ICPO) for
206 their important advocacy work.

207

208 **Author Contributions:** NEWK optimized the experimental protocol and performed the
209 experiments. CDB provided technical assistance. NEWK, FS, AH, LS, JOC and DOS recruited
210 study participants. NEWK processed and biobanked samples. NEWK, JOC and DOS analysed
211 the clinical cohorts. NEWK and AEH analysed the data and drafted the manuscript. AEH,
212 DOS, JOC, PM and NEWK conceptualized/designed the study and approved the final
213 manuscript as submitted.

214

215 **Competing interests:** The authors declare no competing interests.

216

217 **Data availability statement:** The datasets generated during and/or analysed during the
218 current study are available from the corresponding author on reasonable request.

219

220 **References**

221

222 1. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with
223 obesity and COVID-19: A global perspective on the epidemiology and biological relationships.
224 *Obes Rev.* 2020;21(11):e13128.

225 2. Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P, et al.
226 Associations between body-mass index and COVID-19 severity in 6.9 million people in
227 England: a prospective, community-based, cohort study. *The Lancet Diabetes &*
228 *Endocrinology.* 2021;9(6):350-9.

229 3. Banga N, Guss P, Banga A, Rosenman KD. Incidence and variables associated with
230 inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical
231 students. *Vaccine.* 2014;32(8):979-83.

232 4. Eliakim A, Schwindt C, Zaldivar F, Casali P, Cooper DM. Reduced tetanus antibody
233 titers in overweight children. *Autoimmunity.* 2006;39(2):137-41.

234 5. Weber DJ, Rutala WA, Samsa GP, Bradshaw SE, Lemon SM. Impaired
235 immunogenicity of hepatitis B vaccine in obese persons. *N Engl J Med.* 1986;314(21):1393.

236 6. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al.
237 Obesity is associated with impaired immune response to influenza vaccination in humans. *Int*
238 *J Obes (Lond).* 2012;36(8):1072-7.

239 7. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.
240 Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations
241 with age and disease severity. *Cell.* 2020.

- 242 8. Collier AY, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential
243 Kinetics of Immune Responses Elicited by Covid-19 Vaccines. *N Engl J Med.*
244 2021;385(21):2010-2.
- 245 9. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2
246 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha
247 to Omicron. *Cell.* 2022;185(5):847-59 e11.
- 248 10. Goncalves Pereira MH, Figueiredo MM, Queiroz CP, Magalhaes TVB, Mafra A, Diniz
249 LMO, et al. T-cells producing multiple combinations of IFN γ , TNF and IL10 are
250 associated with mild forms of dengue infection. *Immunology.* 2020;160(1):90-102.
- 251 11. O'Shea D, Corrigan M, Dunne MR, Jackson R, Woods C, Gaoatswe G, et al. Changes
252 in human dendritic cell number and function in severe obesity may contribute to increased
253 susceptibility to viral infection. *Int J Obes (Lond).* 2013;37(11):1510-3.
- 254 12. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al.
255 Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer*
256 *Cell.* 2021;39(8):1081-90 e2.
- 257 13. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al.
258 Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant
259 Recipients. *JAMA.* 2021;325(21):2204-6.
- 260 14. Hassold N, Brichler S, Ouedraogo E, Leclerc D, Carroue S, Gater Y, et al. Impaired
261 antibody response to COVID-19 vaccination in advanced HIV infection. *AIDS.*
262 2022;36(4):F1-F5.
- 263 15. Green WD, Beck MA. Obesity Impairs the Adaptive Immune Response to Influenza
264 Virus. *Ann Am Thorac Soc.* 2017;14(Supplement_5):S406-S9.

- 265 16. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity,
266 smoking habit, and hypertension are associated with lower antibody titres in response to
267 COVID-19 mRNA vaccine. *Diabetes Metab Res Rev.* 2022;38(1):e3465.
- 268 17. Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
269 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med.*
270 2021;385(19):1761-73.
- 271 18. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al.
272 Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J*
273 *Med.* 2021;385(19):1774-85.
- 274 19. Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike
275 Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19
276 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and
277 Adverse Reactions. *Front Immunol.* 2021;12:779212.
- 278 20. Mallon PWG, Tinago W, Leon AG, McCann K, Kenny G, McGettrick P, et al.
279 Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses.
280 *Open Forum Infect Dis.* 2021;8(8):ofab122.

281
282
283

284 **Figure 1. SARS-CoV-2 spike specific T cell responses of subjects at 5 months following**
285 **ChAdOx1 COVID-19 vaccination.**

286 (A) Representative flow cytometry gating strategy for detection of T cell subsets (CD8⁺ or
287 CD4⁺) and their cytokine production. (B-E) Scatter plot showing the frequencies of cytokine
288 expressing T cells (CD8⁺ or CD4⁺) from vaccinated individuals following overnight stimulation
289 with SARS-CoV-2 spike peptide pools. (F-I) Frequencies of T cell subsets (CD8⁺ or CD4⁺) in
290 COVID-19 vaccinated individuals with (PWO) or without obesity (controls), producing cytokine
291 (TNF α , IFN γ) in response to overnight stimulation with SARS-CoV-2 spike peptide pools.
292 Where bars are present they denote median. Statistical comparisons across cohorts were
293 performed with the Wilcoxon test for paired data (B-E) and Mann-Whitney U test for unpaired
294 data (F-I). Data for (F-I) were background subtracted against negative control.

295






Figure 1

Table 1: Participant Characteristics		
	People with Obesity	Controls
Total number (%)	30 (60)	20 (40)
Age (years)	60.5 (47.5-67.0)	63.0 (60.3-65.0)
BMI (kg/m²)	39.1 (32.6-47.0)	26 (22.8-27.8)
Female (n [%])	18 (60)	8 (40)
Days from second vaccine dose	158 (153-166)	154 (152-158)
<i>Data are median (IQR) unless specified. BMI: body mass index.</i>		